Evidence map›Paper›PMID 30082655›Full record

ArticleMolecules (Basel, Switzerland)2018

16-Hydroxycleroda-3,13-dien-15,16-olide and N-Methyl-Actinodaphine Potentiate Tamoxifen-Induced Cell Death in Breast Cancer.

Bharath Kumar Velmurugan, Po-Chih Wang, Ching-Feng Weng

Open access · goldAbstract read
In one paragraph

Article in Molecules (Basel, Switzerland), 2018. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 7 papers.

0numbers the graph read from it
0cells of the map it votes in
7citing papers in PubMed
0.9field-weighted citation impact, top 21% of its field
1 · What the graph read from it

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

2 · The registry

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.

3 · Its place in the literature

Who cites it

7 citing papers in PubMed, 9 citations in OpenAlex.

  1. Review
  2. The PI3K Inhibitor HCD Promotes Caspase Activation in Head and Neck Squamous Cells by Upregulating the Extrinsic and Intrinsic Apoptosis Pathways.Journal of oral pathology & medicine : official publication of the International Association of Oral Pathologists and the American Academy of Oral Pathology · 2026
    Article
  3. Clerodane Diterpenoids from an Edible PlantMolecules (Basel, Switzerland) · 2021
    Article
  4. Phytochemicals fromMolecules (Basel, Switzerland) · 2021
    Review
  5. Article
  6. Article
  7. Article
4 · The record

Corrections and comments

PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.

5 · Who and what money

Authors and funding

3 authors at 2 institutions in 2 countries.

Bharath Kumar VelmuruganFaculty of Applied Sciences, Ton Duc Thang University, Ho Chi Minh City, Vietnam. bharath.kumar.velmurugan@tdt.edu.vn.ORCID 0000-0002-4786-9913
Po-Chih WangDepartment of Life Science and Institute of Biotechnology, National Dong Hwa University, Hualien 97401, Taiwan. a2704490@gmail.com.
Ching-Feng WengDepartment of Life Science and Institute of Biotechnology, National Dong Hwa University, Hualien 97401, Taiwan. cfweng@gms.ndhu.edu.tw.
National Dong Hwa University · TWTon Duc Thang University · VN

Funding

No grant is acknowledged in the PubMed record.

6 · The paper itself

Abstract

In this study, we investigated whether 16-hydroxycleroda-3,13-dien-15,16-olide (HCD) and N-methyl-actinodaphine (MA) could sensitize breast cancer cells to Tamoxifen (TMX) treatment. MA or HCD alone or in combination with TMX dose-dependently inhibited MCF-7 and MDA-MB-231 cell growth, with a more potent inhibition on MDA-MB 231 cells. Furthermore, this novel combination significantly induced S and G2/M cell cycle phase in MDA-MB 231 than MCF-7 cells. Further determination of the apoptotic induction showed that MA or HCD and TMX combination inhibited MDA-MB-231 and MCF-7 cancer cells by upregulating Bax and by downregulating Bcl-2 mRNA and protein expression without altering Caspase-8 and Caspase-12 expression. These results suggest that MA or HCD pretreatment may potentiate the anti-tumor effect of tamoxifen on breast cancer.

Indexed as

Antineoplastic AgentsApoptosisBreast NeoplasmsCaspase 12Caspase 8Cell CycleCell Line, TumorCell ProliferationDioxolanesFemaleHumansMCF-7 CellsTamoxifenactinodaphineAntineoplastic AgentsCaspase 12Caspase 8DioxolanesTamoxifenapoptosisBaxBcl2HCDMATMX

Identifiers

PMID30082655
PMCPMC6222426
OpenAlexW2887856722

What OpenQuestion holds

Textmetadata
LicenceCC BY
Read underepoch 390

Registered trials

None linked

Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.